ITGAL and B-cell chronic lymphocytic leukemia: Treatment with lenalidomide, a clinically active drug used in hematologic cancers [72], restored Rho GTPase signaling in T cells, rescued LFA-1 function [71] and improved immune synapse formation between T and B-CLL cells [70].